Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies

References

• Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol 2009;472:323–42.
   PubMedGoogle Scholar
• Lecolle K, Begard S, Caillierez R, Demeyer D, Grellier E, Loyens A, et al. Sstr2A: A relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors. Gene Ther 2013;20:283–97.
   PubMed Web of Science ®Google Scholar
• Pozsgai E, Schally AV, Halmos G, Rick F, Bellyei S. The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. Horm Metab Res 2010;42:781–6.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Hofer S, Eichhorn K, Wasner M, Zimmerer S, Freitag P, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: An extended pilot study. Eur J Nucl Med Mol Imaging 2002;29:486–93.
   PubMed Web of Science ®Google Scholar
• Heute D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with 90Y-DOTATOC. J Nucl Med 2010;51:397–400.
   PubMed Web of Science ®Google Scholar
• Malinen E, Muren LP. Image guided therapy – Do we get the picture?Acta Oncol 2014;53:3–5.
   PubMed Web of Science ®Google Scholar
• Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011;41:314–21.
   PubMed Web of Science ®Google Scholar
• Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol 2013;52: 514–20.
   PubMed Web of Science ®Google Scholar
• Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of pharmacokinetics of radioiodinated Tyr(3)-octreotide by conjugation with carbohydrates. Bioconjug Chem 2002;13:1021–30.
   PubMed Web of Science ®Google Scholar
• Li XG, Helariutta K, Roivainen A, Jalkanen S, Knuuti J, Airaksinen AJ. Using 5-deoxy-5-[18F]fluororibose to glycosylate peptides for positron emission tomography. Nat Protoc 2014;9:138–45.
   PubMed Web of Science ®Google Scholar
• Laerum OD, Rajewsky MF. Neoplastic transformation of fetal rat brain cells in culture after exposure to ethylnitrosourea in vivo. J Natl Cancer Inst 1975;55:1177–87.
   PubMedGoogle Scholar
• Tyynelä, Sandmair A, Turunen M, Vanninen R, Vainio P, Kauppinen R, et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene therapy in BT4C rat glioma model. Cancer Gene Ther 2002;9:917–24.
   PubMed Web of Science ®Google Scholar
• Li XG, Autio A, Ahtinen H, Helariutta K, Liljenbäck H, Jalkanen S, et al. Translating the concept of peptide labeling with 5-deoxy-5-[18F]fluororibose into preclinical practice: 18F-labeling of Siglec-9 peptide for PET imaging of inflammation. Chem Commun (Camb) 2013;49:3682–4.
   PubMed Web of Science ®Google Scholar
• Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009;50:936–41.
   PubMed Web of Science ®Google Scholar
• Korner M, Waser B, Schonbrunn A, Perren A, Reubi JC. Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 2012;36:242–52.
   PubMed Web of Science ®Google Scholar
• Watson JC, Balster DA, Gebhardt BM, O’Dorisio TM, O’Dorisio MS, Espenan GD, et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br J Cancer 2001;85:266–72.
   PubMed Web of Science ®Google Scholar
• Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995;57:1249–65.
   PubMed Web of Science ®Google Scholar
• Thorsen F, Ersland L, Nordli H, Enger PO, Huszthy PC, Lundervold A, et al. Imaging of experimental rat gliomas using a clinical MR scanner. J Neurooncol 2003;63:225–31.
   PubMed Web of Science ®Google Scholar
• Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326–36.
   PubMed Web of Science ®Google Scholar
• Schmidt KC, Smith CB. Resolution, sensitivity and precision with autoradiography and small animal positron emission tomography: Implications for functional brain imaging in animal research. Nucl Med Biol 2005;32:719–25.
   PubMed Web of Science ®Google Scholar
• Busk M, Jakobsen S, Horsman MR, Mortensen LS, Iversen AB, Overgaard J, et al. PET imaging of tumor hypoxia using 18F-labeled pimonidazole. Acta Oncol 2013;52:1300–7.
   PubMed Web of Science ®Google Scholar
• Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003; 30:1338–47.
   PubMed Web of Science ®Google Scholar
• Miederer M, Seidl S, Buck A, Scheidhauer K, Wester HJ, Schwaiger M, et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 2009;36:48–52.
   PubMed Web of Science ®Google Scholar